U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Metastatic Lung Adenocarcinoma

MedGen UID:
1660921
•Concept ID:
C4744444
•
Neoplastic Process

Definition

Lung adenocarcinoma that has spread from its original site of growth to another anatomic site. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVMetastatic Lung Adenocarcinoma

Professional guidelines

PubMed

Real-World Molecular Testing and Treatment Patterns in Brazilian Patients with Newly Diagnosed Locally Advanced or Metastatic NSCLC.
Cronemberger E, Baldotto C, Marinho F, De Marchi P, Araújo LH, Franke F, Salles P, Calabrich A, Almeida T, Custodio MG, Maria AS, Pereira MH, Castro G Jr
Clinics (Sao Paulo) 2020;75:e1777. Epub 2020 Oct 19 doi: 10.6061/clinics/2020/e1777. PMID: 33084767Free PMC Article
Utility of GATA3 in the differential diagnosis of pheochromocytoma.
Perrino CM, Ho A, Dall CP, Zynger DL
Histopathology 2017 Sep;71(3):475-479. Epub 2017 Jun 5 doi: 10.1111/his.13229. PMID: 28374498
Ceritinib for the treatment of late-stage (metastatic) non-small cell lung cancer.
Massarelli E, Papadimitrakopoulou V
Clin Cancer Res 2015 Feb 15;21(4):670-4. Epub 2015 Jan 6 doi: 10.1158/1078-0432.CCR-14-1291. PMID: 25564153

Recent clinical studies

Etiology

Marantic Endocarditis in Metastatic Lung Adenocarcinoma.
Palicherla A, Pusapati S, Anugula D, Thandra A
Methodist Debakey Cardiovasc J 2023;19(4):100-103. Epub 2023 Aug 1 doi: 10.14797/mdcvj.1243. PMID: 37547896Free PMC Article
Correlation of Programmed Death-Ligand 1 Expression With Lung Adenocarcinoma Histologic and Molecular Subgroups in Primary and Metastatic Sites.
Argyropoulos K, Basu A, Park K, Zhou F, Moreira AL, Narula N
Mod Pathol 2023 Sep;36(9):100245. Epub 2023 Jun 10 doi: 10.1016/j.modpat.2023.100245. PMID: 37307880
Retrospective Data Analysis of Patients With Metastatic Lung Adenocarcinoma With or Without KRAS-Mutation or TTF1-Expression.
Moeller M, Schaedlich F, Schuette W
Cancer Control 2022 Jan-Dec;29:10732748221126949. doi: 10.1177/10732748221126949. PMID: 36355617Free PMC Article
Non-bacterial thrombotic endocarditis and metastatic lung adenocarcinoma.
Zhou Y, Yee Y, Qin Y
BMJ Case Rep 2021 Jul 27;14(7) doi: 10.1136/bcr-2021-242948. PMID: 34315738Free PMC Article
Prognostic factors of EGFR-mutated metastatic adenocarcinoma of lung.
Ng KS, King Sun C, Boom Ting K, Ting Kun AY
Eur J Radiol 2020 Feb;123:108780. Epub 2019 Dec 10 doi: 10.1016/j.ejrad.2019.108780. PMID: 31846863

Diagnosis

Metastatic Lung Adenocarcinoma Presenting as Hydrocele.
Gupta S, Erickson LA
Mayo Clin Proc 2023 Dec;98(12):1894-1896. doi: 10.1016/j.mayocp.2023.08.009. PMID: 38044007
A user's guide to lorlatinib.
Nagasaka M, Ge Y, Sukari A, Kukreja G, Ou SI
Crit Rev Oncol Hematol 2020 Jul;151:102969. Epub 2020 May 11 doi: 10.1016/j.critrevonc.2020.102969. PMID: 32416346
Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma.
Kim N, Kim HK, Lee K, Hong Y, Cho JH, Choi JW, Lee JI, Suh YL, Ku BM, Eum HH, Choi S, Choi YL, Joung JG, Park WY, Jung HA, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ, Lee HO
Nat Commun 2020 May 8;11(1):2285. doi: 10.1038/s41467-020-16164-1. PMID: 32385277Free PMC Article
Metastatic Lung Adenocarcinoma.
Kolomeyer AM, Brucker AJ, O'Brien JM
Ophthalmology 2017 Jul;124(7):969. doi: 10.1016/j.ophtha.2016.12.036. PMID: 28645343
Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.
Jordan EJ, Kim HR, Arcila ME, Barron D, Chakravarty D, Gao J, Chang MT, Ni A, Kundra R, Jonsson P, Jayakumaran G, Gao SP, Johnsen HC, Hanrahan AJ, Zehir A, Rekhtman N, Ginsberg MS, Li BT, Yu HA, Paik PK, Drilon A, Hellmann MD, Reales DN, Benayed R, Rusch VW, Kris MG, Chaft JE, Baselga J, Taylor BS, Schultz N, Rudin CM, Hyman DM, Berger MF, Solit DB, Ladanyi M, Riely GJ
Cancer Discov 2017 Jun;7(6):596-609. Epub 2017 Mar 23 doi: 10.1158/2159-8290.CD-16-1337. PMID: 28336552Free PMC Article

Therapy

Lemierre's syndrome masking metastatic lung adenocarcinoma.
Naran R, Dattani V, Madani Y
Thorax 2022 Mar;77(3):314-316. Epub 2022 Jan 7 doi: 10.1136/thoraxjnl-2021-217330. PMID: 34996853
A user's guide to lorlatinib.
Nagasaka M, Ge Y, Sukari A, Kukreja G, Ou SI
Crit Rev Oncol Hematol 2020 Jul;151:102969. Epub 2020 May 11 doi: 10.1016/j.critrevonc.2020.102969. PMID: 32416346
First-Line Therapies for Metastatic Lung Adenocarcinoma Without a Driver Mutation.
Bodor JN, Kasireddy V, Borghaei H
J Oncol Pract 2018 Sep;14(9):529-535. doi: 10.1200/JOP.18.00250. PMID: 30205771
Metastatic Lung Adenocarcinoma.
Kolomeyer AM, Brucker AJ, O'Brien JM
Ophthalmology 2017 Jul;124(7):969. doi: 10.1016/j.ophtha.2016.12.036. PMID: 28645343
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.
Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, Su WC, Bennouna J, Kato T, Gorbunova V, Lee KH, Shah R, Massey D, Zazulina V, Shahidi M, Schuler M
J Clin Oncol 2013 Sep 20;31(27):3327-34. Epub 2013 Jul 1 doi: 10.1200/JCO.2012.44.2806. PMID: 23816960

Prognosis

m(6) A-Dependent Modulation via IGF2BP3/MCM5/Notch Axis Promotes Partial EMT and LUAD Metastasis.
Yang X, Bai Q, Chen W, Liang J, Wang F, Gu W, Liu L, Li Q, Chen Z, Zhou A, Long J, Tian H, Wu J, Ding X, Zhou N, Li M, Yang Y, Cai J
Adv Sci (Weinh) 2023 Jul;10(20):e2206744. Epub 2023 May 12 doi: 10.1002/advs.202206744. PMID: 37171793Free PMC Article
Comparative molecular profiling of distant metastatic and non-distant metastatic lung adenocarcinoma.
Chen Z, Chen G, Wang Z, Yu J, Zhang H, Mao B, Ma H
Neoplasma 2021 Mar;68(2):253-261. Epub 2020 Sep 17 doi: 10.4149/neo_2020_200203N103. PMID: 32940041
Prognostic factors of EGFR-mutated metastatic adenocarcinoma of lung.
Ng KS, King Sun C, Boom Ting K, Ting Kun AY
Eur J Radiol 2020 Feb;123:108780. Epub 2019 Dec 10 doi: 10.1016/j.ejrad.2019.108780. PMID: 31846863
First-Line Therapies for Metastatic Lung Adenocarcinoma Without a Driver Mutation.
Bodor JN, Kasireddy V, Borghaei H
J Oncol Pract 2018 Sep;14(9):529-535. doi: 10.1200/JOP.18.00250. PMID: 30205771
Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.
Jordan EJ, Kim HR, Arcila ME, Barron D, Chakravarty D, Gao J, Chang MT, Ni A, Kundra R, Jonsson P, Jayakumaran G, Gao SP, Johnsen HC, Hanrahan AJ, Zehir A, Rekhtman N, Ginsberg MS, Li BT, Yu HA, Paik PK, Drilon A, Hellmann MD, Reales DN, Benayed R, Rusch VW, Kris MG, Chaft JE, Baselga J, Taylor BS, Schultz N, Rudin CM, Hyman DM, Berger MF, Solit DB, Ladanyi M, Riely GJ
Cancer Discov 2017 Jun;7(6):596-609. Epub 2017 Mar 23 doi: 10.1158/2159-8290.CD-16-1337. PMID: 28336552Free PMC Article

Clinical prediction guides

Organ-specific heterogeneity in tumor-infiltrating immune cells and cancer antigen expression in primary and autologous metastatic lung adenocarcinoma.
Restle D, Dux J, Li X, Byun AJ, Choe JK, Li Y, Vaghjiani RG, Thomas C, Misawa K, Tan KS, Jones DR, Chintala NK, Adusumilli PS
J Immunother Cancer 2023 Jun;11(6) doi: 10.1136/jitc-2022-006609. PMID: 37349126Free PMC Article
Prognostic factors and survival prediction for patients with metastatic lung adenocarcinoma: A population-based study.
Wu B, Chen J, Zhang X, Feng N, Xiang Z, Wei Y, Xie J, Zhang W
Medicine (Baltimore) 2022 Dec 9;101(49):e32217. doi: 10.1097/MD.0000000000032217. PMID: 36626448Free PMC Article
Comparative molecular profiling of distant metastatic and non-distant metastatic lung adenocarcinoma.
Chen Z, Chen G, Wang Z, Yu J, Zhang H, Mao B, Ma H
Neoplasma 2021 Mar;68(2):253-261. Epub 2020 Sep 17 doi: 10.4149/neo_2020_200203N103. PMID: 32940041
Single-cell transcriptome analysis demonstrates inter-patient and intra-tumor heterogeneity in primary and metastatic lung adenocarcinoma.
Liu Y, Ye G, Huang L, Zhang C, Sheng Y, Wu B, Han L, Wu C, Dong B, Qi Y
Aging (Albany NY) 2020 Nov 10;12(21):21559-21581. doi: 10.18632/aging.103945. PMID: 33170151Free PMC Article
Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.
Jordan EJ, Kim HR, Arcila ME, Barron D, Chakravarty D, Gao J, Chang MT, Ni A, Kundra R, Jonsson P, Jayakumaran G, Gao SP, Johnsen HC, Hanrahan AJ, Zehir A, Rekhtman N, Ginsberg MS, Li BT, Yu HA, Paik PK, Drilon A, Hellmann MD, Reales DN, Benayed R, Rusch VW, Kris MG, Chaft JE, Baselga J, Taylor BS, Schultz N, Rudin CM, Hyman DM, Berger MF, Solit DB, Ladanyi M, Riely GJ
Cancer Discov 2017 Jun;7(6):596-609. Epub 2017 Mar 23 doi: 10.1158/2159-8290.CD-16-1337. PMID: 28336552Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...